Why the study?
Is socioeconomic deprivation associated with increased cardiovascular disease burden and altered antihypertensive medication utilization in Hungary?
Is socioeconomic deprivation associated with increased cardiovascular disease burden and altered antihypertensive medication utilization in Hungary?
Socioeconomic deprivation in Hungary is strongly associated with increased CVD mortality and morbidity, highlighting a potential underdiagnosis of hypertension in highly deprived areas.
Suggests possible hypertension underdiagnosis in deprived Hungarian areas; leaves open whether targeted strategies could address excess CVD burden.
The wide life expectancy gap between the old and new member states of the European Union is most strongly related to the high rate of premature mortality caused by cardiovascular diseases (CVDs). To learn more about the background of this gap, the relationship of socioeconomic status (SES) with CVD mortality, morbidity and the utilization of antihypertensive drugs was studied in Hungary, a Central-Eastern European country with an extremely high relative risk of premature CVD mortality. Risk analysis capabilities were used to estimate the relationships between SES, which was characterized by tertiles of a multidimensional composite indicator (the deprivation index) and CVD burden (mortality and morbidity) as well as the antihypertensive medications at the district level in Hungary. The excess risks caused by premature mortality from CVDs showed a strong correlation with deprivation using the Rapid Inquiry Facility. The distribution of prevalence values related to these diseases was found to be similar, but in the areas of highest deprivation, where the prevalence of chronic ischaemic heart diseases and cerebrovascular diseases was found to be higher than the national average by 30 and 20%, the prevalence of hypertension exceeded the national average by only 4%. A linear association between the relative frequency of prescriptions/redemptions and deprivation for most antihypertensive drugs, except angiotensinogen receptor blockers, was shown. More intense screening for hypertension is proposed to improve the control of CVDs in countries affected by high disease burden.
No takes yet. Share an insight, caveat, or question.
Boruzs et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: